Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
- 25 October 2007
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 62 (3) , 433-437
Abstract
Purpose Histone deacetylases (HDAC) are involved in the regulation of gene transcription. Aberrant HDAC activity has been associated with tumorigenesis, and, therefore, HDACs are potential targets for the treatment of cancers, including tumors of the central nervous system (CNS). Belinostat is a novel, potent, pan-HDAC inhibitor with antiproliferative activity on a wide variety of tumor cell lines. We studied the cerebrospinal fluid (CSF) penetration of intravenous (IV) belinostat in a non-human primate model as a surrogate for blood:brain barrier penetration. Design Five adult rhesus monkeys received increasing doses of belinostat (10–60 mg/kg) as a 30-min IV infusion. Serial blood and CSF samples were collected over 48 h. Plasma and CSF concentrations of belinostat were quantified with an LC/MS/MS assay. Pharmacokinetic parameters were calculated using non-compartmental methods, and CSF penetration is expressed as the ratio of the area under the concentration-time curve (AUC) in CSF to the AUC in plasma. Results Belinostat was cleared rapidly from plasma with a half-life of 1.0 h, a mean residence time of 0.47 h, and a clearance of 425 ml/min/m2. CSF penetration of belinostat was limited. CSF drug exposure was <1% of plasma drug exposure and <10% of free (non-protein bound) plasma drug exposure. Conclusion IV belinostat is rapidly cleared from plasma and has limited penetration into the CSF.Keywords
This publication has 15 references indexed in Scilit:
- 319 POSTER Biochemical characterization of PXD101, a small molecule HDAC inhibitor, and a library of additional compounds on recombinant class I and II HDAC isoformsEuropean Journal of Cancer Supplements, 2006
- A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumoursJournal of Clinical Oncology, 2005
- Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's diseaseProceedings of the National Academy of Sciences, 2003
- Histone Deacetylase in Carcinogenesis and Its Inhibitors as Anti-cancer AgentsBMB Reports, 2003
- Inhibitors of Histone Deacetylation Downregulate the Expression of Endothelial Nitric Oxide Synthase and Compromise Endothelial Cell Function in Vasorelaxation and AngiogenesisCirculation Research, 2002
- Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cellsBrain Tumor Pathology, 2002
- Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation2002
- Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein BadBrain Tumor Pathology, 2001
- Histone acetylation and diseaseCellular and Molecular Life Sciences, 2001
- A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylasesProceedings of the National Academy of Sciences, 1998